Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US11492411B2 · kind B2 · utility
0Cited by
59References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 4, 2019 |
| Grant date | Nov 8, 2022 |
| Priority date | — |
| Expiry date | Nov 26, 2040 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S435/81
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.